What is the address of VALOIS?

The registered office of VALOIS is located at Avenue Jean Mermoz 1 box 4, 6041 Charleroi.

Is VALOIS still active?

Yes. According to the CBE (29 October 2026) VALOIS is active, legal situation “Normale toestand”, started on 1 January 1968.

Is VALOIS registered on Peppol?

No, VALOIS is currently not registered on the Peppol network.

What is the enterprise number of VALOIS?

The enterprise number of VALOIS is BE0402251773.

When was VALOIS founded?

VALOIS was founded on 1 January 1968.

Who are the directors of VALOIS?

According to the 2025 annual accounts, the directors of VALOIS are: CMHC SRL, JMHC SRL, EMHC SRL.

Is VALOIS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 1 January 1968; 4 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did VALOIS make in 2025?

VALOIS recorded a loss after taxes of € 268,519 in financial year 2025.

VALOIS (Public Limited) - Charleroi - BE0402251773

Dossier VALOIS, printed on 29 October 2026 from databakkes.be/en/0402251773/valois. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2023 and 2025.
Busy address KBO

19 other companies have their registered office at the same address; threshold 10.
Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

VALOIS from Charleroi, company number BE0402251773, closed financial year 2025 with a result of € -268,519 after tax. Compared with financial year 2023, the result moved from € -86,821 to € -268,519. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 23, 2026.

What it is worth Healthy

€ 8.8 million

▼ 4% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -268,519

▼ 209 % more loss than in 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 313,388

▲ € 278,940 vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -7.9 million.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 32,549

▲ € 31,267 vs 2023

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 247 days on average.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2025	Change 2023 → 2025
Profit after taxes	€ -56,069 Profit after taxes 2021: € -56,069 First fiscal year in the series	€ 488,870 Profit after taxes 2022: € 488,870 ▲ € 544,939 vs 2021 (€ -56,069) Favourable step	€ -86,821 Profit after taxes 2023: € -86,821 ▼ € 575,691 vs 2022 (€ 488,870) Unfavourable step	€ -268,519 Profit after taxes 2025: € -268,519 ▼ € 181,698 vs 2023 (€ -86,821) Unfavourable step	▼ € 181,698
Equity	€ 8,710,778 Equity 2021: € 8,710,778 First fiscal year in the series	€ 9,199,648 Equity 2022: € 9,199,648 ▲ 6% vs 2021 (€ 8,710,778) Favourable step	€ 9,112,827 Equity 2023: € 9,112,827 ▼ 1% vs 2022 (€ 9,199,648) Unfavourable step	€ 8,752,986 Equity 2025: € 8,752,986 ▼ 4% vs 2023 (€ 9,112,827) Unfavourable step	▼ 4%
Total debts	€ 2,759,335 Total debts 2021: € 2,759,335 First fiscal year in the series	€ 2,693,398 Total debts 2022: € 2,693,398 ▼ 2% vs 2021 (€ 2,759,335) Favourable step	€ 1,916,712 Total debts 2023: € 1,916,712 ▼ 29% vs 2022 (€ 2,693,398) Favourable step	€ 5,523,413 Total debts 2025: € 5,523,413 ▲ 188% vs 2023 (€ 1,916,712) Unfavourable step	▲ 188%
Cash	€ 231,444 Cash 2021: € 231,444 First fiscal year in the series	€ 908,078 Cash 2022: € 908,078 ▲ 292% vs 2021 (€ 231,444) Favourable step	€ 34,448 Cash 2023: € 34,448 ▼ 96% vs 2022 (€ 908,078) Unfavourable step	€ 313,388 Cash 2025: € 313,388 ▲ € 278,940 vs 2023 (€ 34,448) Favourable step	▲ € 278,940
Retained profit	€ -7,950,722 Retained profit 2021: € -7,950,722 First fiscal year in the series	€ -7,461,852 Retained profit 2022: € -7,461,852 ▲ € 488,870 vs 2021 (€ -7,950,722) Favourable step	€ -7,548,673 Retained profit 2023: € -7,548,673 ▼ € 86,821 vs 2022 (€ -7,461,852) Unfavourable step	€ -7,908,514 Retained profit 2025: € -7,908,514 ▼ € 359,841 vs 2023 (€ -7,548,673) Unfavourable step	▼ € 359,841
Balance sheet total	€ 11,470,113 Balance sheet total 2021: € 11,470,113 First fiscal year in the series	€ 11,893,046 Balance sheet total 2022: € 11,893,046 ▲ 4% vs 2021 (€ 11,470,113) Unchanged	€ 11,029,539 Balance sheet total 2023: € 11,029,539 ▼ 7% vs 2022 (€ 11,893,046) Unchanged	€ 14,276,399 Balance sheet total 2025: € 14,276,399 ▲ 29% vs 2023 (€ 11,029,539) Unchanged	▲ 29%

Key figures of VALOIS, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to VALOIS?

What happened at VALOIS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2028 CMHC SRL stepped down as director. NBB
2028 JMHC SRL stepped down as director. NBB
2028 EMHC SRL stepped down as director. NBB
Apr 23, 2026 New annual accounts for financial year 2025: loss of € 268,519. Source: NBB ↗
2022 CMHC SRL became a director. NBB
2022 JMHC SRL became a director. NBB
2022 EMHC SRL became a director. NBB
Jan 1, 1968 Start of the company according to the CBE. KBO

In short

From € 56,069 loss in 2021 to € 268,519 loss in 2025.

Best year ever: 2022, with € 488,870 profit.

Original PDFs at the National Bank ↗

Management

CMHC 33.3%

EMHC 33.3%

JMHC 33.3%

The stake of CMHC, EMHC, JMHC comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

VALOIS

KITOZYME 43.9%

ASKLEPIOS CAPITAL SRL 30.6%

QUALITY ASSISTANCE 15.9%

KIOMED Pharma 13.5%

The shares are held by CMHC (33.3%), EMHC (33.3%) and JMHC (33.3%). It owns 43.9% of KITOZYME, 30.6% of ASKLEPIOS CAPITAL SRL, 15.9% of QUALITY ASSISTANCE and 13.5% of KIOMED Pharma itself.